FAM19A5 (also called TAFA5) is a novel secretory protein that is primarily expressed in the brain. However, a recent study reported that FAM19A5 is an adipocyte-derived adipokine that regulates vascular smooth muscle function. Furthermore, genome-wide association study (GWAS) and RNA-seq analyses revealed that the FAM19A5 was associated with a variety of diseases and tumorigenesis in peripheral tissues. We investigated FAM19A5 transcript and protein levels in the FAM19A5 peripheral expression 2 peripheral tissues, including adipose tissues from wild-type, FAM19A5 knock-out, and LacZ knock-in mice. In general, total FAM19A5 transcript levels in the central and peripheral nervous systems were higher than levels in any of the peripheral tissues including adipose tissues. Brain tissues expressed similar levels of the FAM19A5 transcript isoforms 1 and 2, whereas expression in the peripheral tissues predominantly expressed isoform 2. In the peripheral tissues, but not the brain, FAM19A5 protein levels in adipose and reproductive tissues were below detectable limits for analysis by Western blot. Additionally, we found that FAM19A5 protein did not interact with the S1PR2 receptor for G-protein-mediated signal transduction, β-arrestin recruitment, and ligandmediated internalization. Instead, FAM19A5 was internalized into HEK293 cells in an extracellular matrix protein-dependent manner. Taken together, the present study determined basal levels of FAM19A5 transcripts and proteins in peripheral tissues, which provides compelling evidence to further investigate the function of FAM19A5 in peripheral tissues under pathological conditions, including metabolic diseases and/or tumorigenesis.
Introduction
Family with sequence similarity 19 member A5 (FAM19A5, also named TAFA5) is a member of the FAM19A protein family, which is highly expressed in the brain 1 . The FAM19A5 gene encodes a secretory protein that has a high degree of amino acid sequence identity across vertebrate species 2 , suggesting functional relevance in vertebrates. Both human and mouse FAM19A5 genes can produce two forms of the transcript, known as isoform 1 and isoform 2, due to the alternative use of the first exon, exon1-1 and exon1-2. As a result, the two FAM19A5 isoform proteins differ in their N-terminal sequences. Isoform 1 produces a precursor protein that is cleaved at the end of the signal peptide to generate a mature, secreted, 89 amino acid protein 3 . Isoform 2, however, can have two different fates. Isoform 2 may generate a protein that associates with the plasma membrane due to a hydrophobic α-helix at the N-terminus 4 . Alternatively, the Nterminal sequence can also serve as a signal peptide, resulting in a secreted protein that is identical to the mature protein produced by isoform 1 3 .
Transcripts for the FAM19A5 gene are abundant in the brain and comparatively sparse in the peripheral tissues 1 . Recently, using FAM19A5-LacZ knock-in (KI) mice, we determined the expression patterns of FAM19A5 during embryogenesis and in the adult brain. We also identified specific cell types in the brain that expressed FAM19A5 5 . FAM19A5 was expressed in the ventricular zone and the ganglionic eminence during a very early stage of brain development. These expression patterns suggest that the function of FAM19A5 is related to the proliferation and differentiation of neural stem cells and oligodendrocyte precursor cells (OPCs) 5 . In the adult brain, X-gal staining combined with immunostaining for cell-type markers revealed that FAM19A5 was expressed in diverse cell types, including neurons, astrocytes, OPCs, and microglia 5 . The expression of FAM19A5 in diverse cell types was consistent with results from single-cell RNA-sequencing of mouse and human brains 6, 7 . Notably, after traumatic brain injury, FAM19A5 expression is significantly elevated in a subset of neuronal populations in the injury penumbra of the cortex and in some OPCs in the corpus callosum 5 , indicating that FAM19A5 contributes to the wound healing process after brain injury.
In addition to its importance in the brain, recent studies suggest that FAM19A5 also has a role in peripheral tissues. FAM19A5 is reported to be involved in the RANKL-induced differentiation of osteoclast precursor cells through interactions with formyl peptide receptor 2 8 . Another study showed that FAM19A5 suppressed neointima formation in injured rat carotid arteries by interacting with the sphingosine-1-phosphate receptor 2 (S1PR2) 3 . In this study, FAM19A5 is primarily produced in adipose tissue. Analysis of human tissue samples by qRT-PCR revealed that FAM19A5 mRNA levels in adipose tissues are higher than brain tissue levels. Furthermore, immunohistochemistry and enzyme-linked immunosorbent assays (ELISAs) for FAM19A5 have shown high levels of FAM19A5 protein in human and rodent adipose tissues 3 . Intriguingly, FAM19A5 mRNA and protein levels are significantly down-regulated in obese and diabetic animals 3 , suggesting a causal relationship between decreased FAM19A5 levels and metabolic disease conditions. However, this result is in part contradictory to a recent observation in humans where individuals with type 2 diabetes had higher FAM19A5 serum levels than those without type 2 diabetes 9 . The public database for human tissue RNA expression reports that FAM19A5 is expressed in the female and male reproductive tissues including the ovaries, uterus, and testis, although absolute levels in these tissues are significantly lower than brain tissue levels 4, 10 .
The open-targets-platform (https://www.targetvalidation.org/) database shows that 47 human diseases are associated with the FAM19A5 gene including Alzheimer's 11, 12 , schizophrenia 13, 14 , bipolar disorder 15 , pancreatic carcinoma 16 , and endometrial neoplasm 17 , among others 18 . Interestingly, the mosaic monosomy of chromosome 22, which includes disruption of the FAM19A5 gene, leads to skeletal abnormalities, low body weight, and neuropsychiatric conditions, including attention deficit hyperactivity disorder, aggression, and autistic symptoms 19 . Recently, the deletion of chromosome 22q13.32, including the FAM19A5 gene, was associated with schizencephaly accompanied by occipital encephalocele 20 . Multiple copies of the FAM19A5 gene have been associated with glioma 21 . Consistent with this finding, FAM19A5 transcript levels are elevated in patients with glioma, pancreatic cancer, and melanoma 22 . Similarly, the Genomic Data Commons (GDC) Data Portal database from the National Cancer Institute (https://portal.gdc.cancer.gov/) lists FAM19A5 mutations in several types of cancer including adenocarcinoma and squamous neoplasia, and in multiple cancer sites including the corpus or cervix uteri, colon, bronchus, and lungs 23 .
The association of FAM19A5 with several disease states has increased the urgency to measure and understand its expression in a variety of peripheral tissues. In the present study, we examined basal levels of FAM19A5 transcripts and proteins in a variety of peripheral tissues using qRT-PCR and Western blotting. The methods were verified with FAM19A5 knock-out (KO) mice. We also identified the cell types that express FAM19A5 with X-gal staining of peripheral tissues from FAM19A5-LacZ knock-in (KI) mice, as previously described 5 . In contrast to previous report 3 , this study also demonstrated that FAM19A5 transcript and protein levels in adipose tissues are very low compared to those in the brain tissues and that S1PR2 does not interact with FAM19A5 protein for receptor-mediated signal transduction, β-arrestin recruitment, and ligand-mediated receptor internalization.
Methods

Animals
C57BL/6J mice were purchased from Nara Biotech (Seoul, Korea) or Orient Bio, Inc. (Seongnam, Korea). Mice were housed in temperature-controlled (22-23°C) conditions with a 12h light/12-h dark light cycle. The mice were given ad libitum standard chow and water. All animal experiments were designed to use the fewest mice possible and anesthesia was administered, when necessary. All animal procedures were approved by the Institutional Animal Care and Use Committee of Korea University (KOREA-2019-0076 and KOREA-2019-0032).
Generation of FAM19A5 knock-out (KO) mice
FAM19A5 KO mice were generated by ToolGen, Inc. (Seoul, Korea) using the CRISPR/Cas9 system 24 . Briefly, single-guide RNAs (sgRNAs) were designed to target a 5'-UTR sequence of exon 1 (left sgRNA, CCGTCTCTGTCGCCATCCAGAGG E1-1) and the 3'-UTR sequence of exon 4 (right sgRNA, CTTGGCACTTAACTCCCAGATGG). Cas9 mRNA and sgRNAs were microinjected into the cytoplasm of C57BL/6J mice zygotes, and the resulting embryos were transferred into the oviducts of IcrTac:ICR pseudo-pregnant foster mothers to produce live founder mice. Founder mice with mutant alleles were screened using genomic DNA PCR to amplify the genomic region spanning the sgRNA target sites. The primer sequences for the founder screening PCR were: Forward, GGGGGTCCCAAGTCACCTAAC, and Reverse, AAGAACTTGGGAGACAGGCAAA. The PCR products from the founder mice were cloned and the corresponding mutations were identified by direct-sequencing analysis (Bionics Co., Ltd., Seoul, Korea). Founder mice with a mutant allele that lacked the 125,000 bp sequence containing exon 1 to exon 4 were bred with wild-type mice. Germline transmission of the mutant allele was determined by genotyping with the following primers: gF1, TCGGTTCACTTTCCGGATCAAT; gR1, AAGAACTTGGGAGACAGGCAAA; gF2, TCCTGGGAGAGGGGAATAGTTT. Homozygous FAM19A5 knock-out (KO) mice were generated by heterozygous intercross breeding.
FAM19A5-LacZ knock-in (KI) mice
FAM19A5-LacZ KI mice were generated by the UC Davis Mouse Biology Program as previously described 5 . The gene-trap method using LacZ as a reporter gene was employed to visualize FAM19A5 expression in tissue sections 25 . Briefly, the target vector containing the IRES-lacZ gene was inserted in front of exon 4 of the FAM19A5 gene. The LacZ gene is expressed independently of the target FAM19A5 gene due to an IRES element. This FAM19A5-targeting vector was delivered to embryonic stem cells by electroporation. We confirmed vector incorporation into the target chromosome by genotyping and chromosome counting of transgenic embryonic stem cells. Selected transgenic embryonic stem cells were injected into blastocysts, and the embryos were implanted into the uterus of female recipient mice. We performed a germline transmission test to check for stable germline expression in the chimeric generation. The generated FAM19A5-LacZ KI chimeric mice were backcrossed onto a C57BL/6J genetic background.
Quantitative real-time polymerase chain reaction (qRT-PCR) analysis
TRIzol reagent (Invitrogen, USA) was used to isolate total RNA from mouse tissues. The analyzed tissues included the cerebral cortex, hippocampus, spinal cord, heart, aorta, kidney, lung, stomach, small intestine, large intestine, pancreas, liver, salivary gland, thymus, spleen, bone marrow, adrenal gland, pituitary gland, thyroid gland, skeletal muscle, white adipose, brown adipose, and skin. One microgram of RNA was reverse-transcribed into complementary DNA with the RevertAid First Strand cDNA Synthesis kit (Thermo Fisher Scientific, USA). The primer sequences used for qRT-PCR were as follows: mFAM19A5-Iso1-F, 5′-GTC CTC AAC TTT TTG GGC ATT C -3′; mFAM19A5-Iso2-F, 5′-GCG ATG CAG CTC CTG AAG -3'; mFAM19A5-Iso1,2-R, 5′-CCC GGT CTA GGG TCA CAA -3′; mFAM19A5-Total-F, 5′-GGC AGA TAG CAG GCA CCA CT -3′; mFAM19A5-Total-R, 5′-GCT GCG ATT GTC AGG AGA CC -3′; mGAPDH-F, 5′-ATC CTG CAC CAC CAA CTG CT -3′; mGAPDH-R, 5′-GGG CCA TCC ACA GTC TTC TG -3′. The CFX96 Touch RT-PCR detection system using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad, USA) was used for qRT-PCR. Gene expression was normalized to GAPDH levels, and the relative quantity of mRNA was calculated using the comparative Cq method.
X-gal staining
X-gal staining was performed as previously described 5 using 10-week-old adult wild-type (WT) littermates (2 males) and FAM19A5-LacZ KI heterozygote (1 male) and homozygote (3 males and 1 female) mice. Mice were perfused with normal saline and 4% paraformaldehyde in 1× phosphate-buffered saline (PBS). Subsequently, brain and peripheral tissues were isolated, fixed in 4% paraformaldehyde for 3 h at 4C and cryoprotected with 30% sucrose in 1× PBS for 36 h at 4C. The cryoprotected tissues were embedded with optimal compound temperature (OCT) and a 30% sucrose compound (2:3 ratio). The embedded blocks were sectioned at 20 μm using a cryostat (Leica, Wetzlar, Germany). Cryosections that were mounted on glass slides were washed twice with 1× PBS for 5 min each, permeabilized with 0.01% sodium deoxycholate and 0.02% Igepal CA-630 in 1× PBS for 15 min and incubated in an X-gal solution for 24 h at 37C in the dark. The X-gal solution contained 1 mg/ml of X-gal, 2 mM magnesium chloride, 5 mM ethylene glycol-bis (2-aminoethylether)-N,N,N′,N′-tetraacetic acid, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 0.01% sodium deoxycholate, and 0.02% Igepal CA-630 in 0.1 M phosphate buffer (PB) at pH 7.4. X-gal-stained sections were washed twice with 1X PBS for 5 min each, counter-stained with Mayer's hematoxylin, dehydrated with graded ethanol and xylene, and mounted with a cover glass.
The tissue-specific X-gal signal was scored according to the following criteria: No X-gal signal in either WT or FAM19A5-LacZ KI mice was indicated by "-". A non-specific X-gal signal detected in both WT and FAM19A5-LacZ KI mice, which was likely due to endogenous β-gal, was represented by "Δ". An ambiguous signal in both WT and FAM19A5-LacZ KI mice was indicated by "Δ/+". Ambiguity was defined as a signal in FAM19A5-LacZ KI mice that appeared stronger than the signal in WT mice or a negligible signal that was only found in FAM19A5-LacZ KI mice. A positive signal observed only in FAM19A5-LacZ KI mice, but not in WT mice was denoted by "+". Among the samples with a positive signal, "1+" indicated a faint positive signal with sparse, cellular blue precipitate, "2+" indicated a weak positive signal with one or more blue precipitate areas per cell, "3+" indicated a moderate positive signal that was observed in many cells, and ">4+" indicated a robust positive signal.
Purification and fluorescence labeling of FAM19A5 protein
Recombinant N-terminal His-tagged FAM19A5 (N-HIS-FAM19A5) with a tobacco etch virus protease recognition sequence was cloned into the vector pCAG1.1 and expressed in Expi293F cells. The supernatant of the transfected cells encoding for N-HIS-FAM19A5 was collected for Ni-NTA affinity chromatography (Qiagen, Germany). Purified N-HIS-FAM19A5 was then digested overnight at 30°C with AcTEV protease (Thermo Fisher Scientific, USA) to remove the His-tag. Following the cleavage reaction, the digestion products were verified by SDS-PAGE and Western blotting analysis. Purified FAM19A5 was used as a Western blotting control. Next, the purified FAM19A5 was labeled with Alexa Fluor 488 or Cy3 using a protein labeling kit (Expedeon, United Kingdom), according to the manufacturer's instructions. Following the reaction, FAM19A5-Alexa 488 (A488) or the Cy3 conjugates were buffer-exchanged into phosphate-buffered saline (PBS) and concentrated using Centricon filters (Millipore, Germany).
Generation of anti-FAM19A5 antibodies
To generate anti-FAM195 chimeric human/chicken monoclonal antibodies, chickens (Gallus gallus domesticus) were immunized with purified N-terminal His-tagged FAM19A5 protein. Total RNA was extracted from the spleen, bursa of Fabricius, and bone marrow of the immunized chickens and cDNA was synthesized. From the synthesized cDNA, a single-chain variable fragment (scFv) library was constructed with the pComb3X-SS vector system (The Scripps Research Institute, La Jolla, CA, USA). Helper phage VCM13 was added to the culture medium for phagemid DNA and phage-displayed scFv extraction. Biopanning was performed using recombinant N-His-FAM19A5-coated magnetic-beads with the phage-displayed scFv. Phage that bound by biopanning were amplified and used for a second round of biopanning. Biopanning was repeated five times and each time the number of washes was increased to identify the highest-affinity phage. ELISA was used to test randomly selected phage-displayed scFv clones from biopanning for affinity against recombinant FAM19A5. The human CК gene was linked to the anti-FAM19A5 antibody sequence that encoded the light chain variable region, and the CH1, CH2, and CH3 genes of human immunoglobulin isotype IgG1 were added to the heavy chain variable region (Genscript, USA). Vectors that encoded the anti-FAM19A5-IgG1 antibody were transfected into HEK293F cells and the recombinant antibody was purified using Protein A beads (RepliGen). Anti-FAM19A5 antibodies that recognized the epitopes formed at N-terminal and Cterminal regions were generated and called N-A5-Ab and C-A5-Ab, respectively. The purified antibodies were conjugated with HRP or Alexa 488/Cy3 using an antibody labeling kit (Expedeon, United Kingdom) according to the manufacturer's instructions.
Antibody-specificity test
HEK293T cells that were stably transfected with genes encoding for the FAM19A family of proteins were lysed in buffer containing 50 mM Tris-HCL (pH 6.8), 2% SDS, 10% glycerol, 100 mM mercaptoethanol, and bromophenol blue. Whole-cell extracts were resolved on SDS-PAGE gels and transferred to prewetted PVDF blotting membranes in a Trans-Blot Turbo apparatus (Bio-Rad, USA). The blots were blocked in Tris-buffered saline containing 0.3% Tween 20 and 5% skim milk followed by incubation with HRP-conjugated N-A5-Ab at room temperature for 3 h. The blots were then washed three times and GE healthcare ECL reagents were applied. Immunoreactive bands were visualized by X-ray film with exposure times of 0.5 or 10 min.
Western blot analysis
Mouse brain tissue was homogenized in buffer containing 20 mM Tris-HCl (pH 7.5), 500 mM NaCl, 5 mM MgCl2, and protease inhibitor cocktail (Thermo Fisher Scientific). Protein quantification of the homogenized tissues was completed with the Pierce BCA Protein Assay (Thermo Fisher Scientific). Brain homogenates were then resolved on Tris-Glycine gels (Invitrogen, USA) and transferred to prewetted PVDF blotting membranes in a Trans-Blot Turbo apparatus (Bio-Rad, USA). The membrane was blocked in Tris-buffered saline containing 0.05% Tween 20 and 5% skim milk, followed by overnight incubation with HRP-conjugated N-A5-Ab at 4C. The blots were then washed three times with Tris-buffered saline (TBS) containing 0.05% Tween 20. After the application of ECL reagents (Thermo Fisher Scientific), the immunoreactive bands were visualized (photographed) with a Mini HD9 (UVItec, Cambridge, UK) system using a 30-sec exposure.
SRE-Luciferase assay for S1PR2 activation
The pcDNA3.1 vector was purchased from Invitrogen (San Diego, Ca, USA). The SREluciferase (SRE-luc) vector containing a single copy of the serum response element (SRE: CCATATTAGG) conjugated to luciferase was purchased from Stratagene (La Jolla, CA, USA). The cDNAs for human S1PR2 were obtained from BRN SCIENCE, INC. The cDNA genes were inserted into the EcoRI and XhoI sites of pcDNA3.1. HEK293 cells were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). Previously, we constructed a HEK293 cell line that stably expressed Gqi and allowed for the induction of Gq-dependent signaling pathways upon activation of a Gi-coupled receptor 26, 27 . For the luciferase assays, HEK293 Gqi cells were seeded 1 day prior to transfection in 48-well plates at a density of 2.5 × 10 4 cells per well. A mixture that included 100 ng of SRE-luc reporter construct, 100 ng of expression plasmid, and lipofectamine 2000 (Invitrogen, CA, USA) was diluted in Opti-MEM (Gibco) and incubated at room temperature for 20 min. The transfection mixture was then added to the cells according to the manufacturer's instructions. Approximately 30-32 h post-transfection, the medium was aspirated and replaced with serum-free Dulbecco's modified Eagle's medium (DMEM) for 16-18 h, followed by incubation with sphingosine-1-phosphate (S1P) or purified FAM19A5 protein for 6 h. Cells were lysed by adding 100 μl of lysis buffer to the wells. Luciferase activity was determined by analyzing 50 μl of each cell extract in a luciferase assay system according to the standard protocol for the Synergy 2 Multi-Mode Microplate Reader (BioTek, Winooski, VT, USA).
Flow-cytometry analysis for FAM19A5 binding to HEK293 cells
To analyze FAM19A5 binding, HEK293 cells were blocked with 1% BSA in 1× PBS for 1hr. The blocked cells were then incubated with 2 μg of FAM19A5-A488 and/or 20 μg of nonlabeled FAM19A5 or fibronectin for 30 min at 4 ℃. FAM19A5-A488 labeled cells were detected by Guava flow-cytometry system (Luminex, Austin, TX, USA) and analyzed using the Guava software.
Confocal imaging for S1PR2 and FAM19A5 internalization
HEK293 cells were seeded at a density of 4.5 × 10 4 cells/well on poly-L-lysine-coated plastic film coverslips in 12-well plates. The following day, the cells were transfected with S1PR2-GFP plasmids (300 ng). One day post-transfection, the cells were incubated in serum-free MEM for 16 h prior to treatment with S1P (Sigma-Aldrich, MO, USA) and FAM19A5. Internalization of FAM19A5-A488 or FAM19A5-Cy3 (10 μg/ml) was also investigated in the presence of 10% serum, fibronectin (200 μg/ml), fibrinogen (200 μg/ml), and laminin (200 μg/ml). For inhibition of FAM19A5 internalization, cells were pretreated with one of various endocytosis inhibitors, including dynasore (80 μM, 30 min), pitstop (30 μM, 15 min), chlorpromazine (10 μg/ml, 30 min), filipin (5 μg/ml, 30 min), and nystatin (25 μg/ml, 30 min) for the indicated time at 37C. Cell images were taken 30 min after the ligand treatment using a confocal laser scanning microscope (Leica TCS-SP8; Leica microsystems, Wetzlar, Germany).
NanoLuc luciferase complementation assay
The NanoLuc luciferase complementation assay to detect S1PR2 and β-arrestin interactions was performed as previously described 28, 29 . Briefly, the NanoBit starter kit containing the plasmids and the necessary reagents to complete the structural complementation assays in this study were a gift from the Promega Company (Madison, Wisconsin, USA). HEK293 cells were maintained in DMEM that was supplemented with 10% FBS, 100 U/ml penicillin G, and 100 μg/ml streptomycin (Gibco). During the experiments, the cells were tested for mycoplasma using a Universal Mycoplasma Detection kit (ATCC). One day prior to transfection, the cells were seeded in poly-L-lysine (Sigma-Aldrich, MO, USA)-coated 96-well plates at a density of 2.5 × 10 4 cells per well. A mixture containing 100 ng of β-arrestin construct with SmBit, 100 ng of S1PR2 with LgBit or Nluc, and 0.4 μl of lipofectamine 2000 (Invitrogen) was prepared and added to each well. Six hours post-transfection, the medium was aspirated and replaced with serum-free DMEM. Twenty-four hours post-transfection, the medium was aspirated and replaced with 100 μl of OPTI-MEM (Gibco) at room temperature. After a 10-min room temperature incubation, 25 μl of furimazine substrate was added and luminescence measurements were recorded every minute for 10 min. Next, 10 μl of ligand was added to each well and luminescence measurements were recorded immediately for 30 min at 1-min intervals (Synergy H1 Hybrid Multi-Mode Reader, BioTek, Winooski, VT, USA).
Data analysis
Data analyses were performed using GraphPad Prism 5 software (GraphPad software, Inc., La Jolla, CA). Data are shown as the means ± standard errors of the mean.
Results
FAM19A5 mRNA levels in peripheral and brain tissues
To determine FAM19A5 transcript levels, tissue samples from the central and peripheral nervous systems, including the cerebral cortex, hippocampus, spinal cord, and dorsal root ganglion, were analyzed with quantitative real-time PCR (qRT-PCR). In addition, tissue samples from the peripheral tissues, including the heart, aorta, kidney, lung, stomach, small intestine, large intestine, pancreas, liver, salivary glands, thymus, spleen, bone marrow, adrenal gland, pituitary gland, thyroid gland, skeletal muscle, adipose tissues, skin, testis, seminal vesicle, coagulating gland, uterus, and ovaries, were also analyzed by qRT-PCR. Transcript levels were detected with specific primer sets for FAM19A5 isoform 1, FAM19A5 isoform 2, and the total transcript ( Figure 1A) . Possible genomic DNA contamination for all tissues was assessed by performing identical PCR reactions on samples that had not been reverse transcribed and showed either no contamination or negligible levels of contamination that did not interfere with qRT-PCR. Transcript levels were compared with GAPDH levels. The FAM19A5 total transcript levels were approximately equal to the sum of the isoform 1 and isoform 2 levels ( Figure 1B , C, D and Table 1 ).
Tissues from the central nervous system (CNS), including the cerebral cortex, hippocampus, and spinal cord, exhibited the highest levels of isoforms1/2 and total FAM19A5 transcripts. DRG, which is a representative peripheral nervous system (PNS) tissue, also exhibited high FAM19A5 transcript levels. For these CNS and PNS tissues, FAM19A5 transcript levels were not significantly different between male and female mice ( Figure 1B , C, D and Table 1 ).
In general, peripheral tissues exhibited very low levels of FAM19A5 transcripts that ranged between 1/100 to 1/10 of the total transcript levels found in CNS tissues. It is also notable that isoform 1 transcripts were negligibly low in all examined peripheral tissues. In contrast, isoform 2 transcripts were moderately expressed in male and female reproductive tissues, and endocrine tissues including the thyroid, pituitary, and adrenal glands. Other tissues including white and brown adipose tissue exhibited low levels of the total transcript and isoform 2 ( Figure 1B , C, D and Table 1 ). 
Table 1. FAM19A5 expression profile of mouse peripheral tissues using qRT-PCR and X-gal staining of wildtype and FAM19A5-LacZ knock-in (+/+) mice.
FAM19A5 expression in peripheral tissues using FAM19A5-LacZ KI mouse
To identify cell types that express the FAM19A5 transcript, X-gal staining of tissue from FAM19A5-LacZ KI mice was used 5 . Positive X-gal staining in diverse cell types including neurons, astrocytes, OPCs, and microglia was consistent with the results of single-cell RNAsequencing of mouse and human brains 6, 7 . In addition, the X-gal signal intensity was highly correlated with the FAM19A5 transcript levels that were measured with qRT-PCR in an earlier study 5 .
Here, we further identified peripheral tissues that express FAM19A5 using FAM19A5-LacZ knock-in mice. X-gal staining was performed for various peripheral tissues including the heart, aorta, kidneys, lungs, stomach, small intestine, large intestine, pancreas, liver, salivary glands (submandibular, sublingual, and parotid gland), thymus, spleen, bone marrow, adrenal gland, pituitary gland, thyroid gland, skeletal muscle, adipose tissues, skin, testis, seminal vesicle, and coagulating gland ( Supplementary Table and Supplementary Figures 1-24 ). The FAM19A5 promoter-driven X-gal signals were not observed in most tissues. The exceptions to this trend were subsets of cardiac muscle cells, smooth muscle cells or mesenteric plexuses of the gastrointestinal tract tissues, inner cortical cells of X-zone in the adrenal gland, myometrial smooth muscle cells in the uterus, and germ cells in the testis and ovary (Figure 2 and Supplementary Figures 1-24) . The X-gal signal intensity observed in these cells was very faint to moderate when compared with the staining in the brain hippocampus (Figure 2 ). X-gal staining in the white and brown adipose tissues was not detected even though these tissues was reported to express high levels of FAM19A5 3 . The X-gal signals observed in WT mice were likely due to tissue-specific high endogenous β-gal expression [30] [31] [32] . The endogenous β-gal-driven X-gal positive tissues included the glomeruli and renal tubules in the kidney, individual cells in the gastrointestinal mucosa, alveolar macrophages, respiratory epithelia in the lung, thymus, and spleen immune cells, thyroid follicles, white and brown adipose tissues, sebaceous skin glands in the skin, and the coagulating gland epithelium, leydig cells in the testis, endometrial glandular epithelium in the uterus, and granulosa and lutein cells in the ovary. (Figure 2 and Supplementary Table and Supplementary  Figures 1-24 ). 
FAM19A5 protein levels in peripheral tissues
FAM19A5 KO mice were generated with the CRISPR/Cas9 system ( Figure 3A and B) and their FAM19A5 transcript and protein levels were measured (Figure 3C , D, and E). Analysis with qRT-PCR indicated that FAM19A5 transcripts for both isoforms 1 and 2 were not detectable in brain tissue from the FAM19A5 KO mice ( Figure 3C) . In contrast, Western blotting of WT brain extracts indicated the presence of both glycosylated and non-glycosylated FAM19A5. After treating the brain extracts with PNGase, which is a deglycosylation enzyme, the intensity of the band corresponding to glycosylated FAM19A5 greatly decreased. Concurrently, the intensity of the band corresponding to non-glycosylated FAM19A5 increased. Neither glycosylated nor nonglycosylated forms of FAM19A5 protein were observed in the brain extracts from FAM19A5 KO mice ( Figure 3D ). Next, we measured FAM19A5 protein levels in white and brown adipose tissues because FAM19A5 expression patterns in these tissues are not well-defined 3 . We also measured FAM19A5 levels in the testis and ovary because they exhibited moderate levels of FAM19A5 transcript. All of the peripheral tissues exhibited FAM19A5 protein levels that were not detectable by Western blotting, which is correlated with the measured FAM19A5 transcript levels ( Figure  3E ). 
FAM19A5 does not interact with S1PR2
The previous study reported that FAM19A5 can regulate blood vessel smooth muscle function by interacting with the S1PR2 3 . We first investigated whether FAM19A5 elicited S1PR2mediated G-protein signaling using an SRE-luc assay system that was coupled to a HEK293-Gqi stable cell line 27 . Treatment with sphingosine-1 phosphate (S1P), a natural agonist for S1PR2, for 6 h substantially increased SRE-luc activity while FAM19A5 failed to show an effect ( Figure 4A) . These data indicated that FAM19A5 protein cannot induce G-protein-mediated signal transduction in S1PR2-expressing cells. Because some biased agonists induce β-arrestin recruitment to SIPR2 independent of G-protein mediated signaling 27 , we explored whether FAM19A5 increased the interaction between S1PR2 and β-arrestin with the NanoLuc luciferase complementation assay 28, 29 . S1P induced an immediate increase in luciferase activity, indicating an interaction between S1PR2 and β-arrestin. FAM19A5 has no effect ( Figure 4B ). Next, we investigated the effect of FAM19A5 on the internalization of S1PR2 using HEK293 cells that expressed a S1PR2-GFP construct. Confocal microscopy images indicated that S1PR2 is primarily localized to the plasma membrane in the absence of ligand treatment. After treatment with S1P for 30 min, the cellular internalization of S1PR2-GFP increased. However, treatment with FAM19A5 did not result in S1PR2-GFP internalization. Furthermore, FAM19A5-Cy3 was internalized regardless of S1PR2 expression ( Figure 4C ). Collectively, these data indicate that FAM19A5 cannot induce either β-arrestin recruitment to S1PR2 or ligand-stimulated internalization of S1PR2. Figure 4 . FAM19A5 protein did not interact with S1PR2. (A) An SRE-luc reporter assay was used to determine S1PR2 receptor activation in response to S1P and FAM19A5. SRE-luc reporter and S1PR2 genes were co-transfected into HEK293 cells that stably expressed Gqi protein. Cells in serum-free medium were then treated with both S1P and FAM19A5 for 6 h and subjected to a luciferase assay system. (B) Nano-luc reporter assay for β-arrestin recruitment to S1PR2. S1PR2-LgBit and β-arrestin-SmBit constructs were co-transfected into HEK293 cells. Under a live cell system, luminescence was determined before and after treatment with S1P and FAM19A5. Data are presented as the mean ± standard error of the mean from three independent experiments. (C) Internalization of S1PR2 in response to S1P and FAM19A5. HEK293 cells were transfected with a S1PR2-GFP construct. Cells were cultured under serumfree conditions for 16 hr and then treated with S1P, naïve FAM19A5, and FAM19A5-Cy3 for 30 min. Cellular locations of S1PR2-GFP in the presence of the ligands were determined using a confocal microscope. Scale bar represents 10 μm.
FAM19A5 internalizes into HEK293 cells in a serum-and extracellular matrix-dependent manner
We examined whether FAM19A5-A488 and non-conjugated FAM19A5 could be internalized into HEK293 cells. The FAM19A5-A488 was readily internalized into the cells ( Figure 5A ) and once internalized, immunocytochemistry revealed that FAM19A5-A488 colocalized with a Cy3-conjugated N-A5-Ab ( Figure 5A ). Immunocytochemistry also indicated that a non-conjugated native form of FAM19A5 internalized into HEK293 cells (Data not shown). FAM19A5 internalization was completely inhibited by pretreatment with dynasore, pitstop, and chlorpromazine, which are blockers for clathrin-dependent internalization ( Figure 5B and data not shown for pitstop and chrlorpromazine). Notably, FAM19A5 internalization was unaffected by filipin and nystatin, which are blockers for caveolin-dependent internalization (Data not shown). Thus, FAM19A5 may interact with a cell surface receptor prior to receptor-mediated internalization through a dynamin/clathrin-dependent manner. FAM19A5 internalization was significantly attenuated by high serum concentrations (10%) ( Figure 5C ) and also by pretreatment with extracellular matrix (ECM) molecules including fibronectin (FN), fibrinogen, and laminin ( Figure 5C ). These inhibition patterns suggest that FAM19A5 internalization is likely mediated by a membrane bound-cell surface molecule that interacts with ECM and/or serum components. FAM19A5 binding and internalization into HEK293 cells was also investigated with FACS analysis ( Figure 5D ). FAM19A5-A488 bound to HEK293 cells ( Figure 5D ), and increased binding was attenuated by pretreatment with naïve FAM19A5. Furthermore, pretreatment with FN decreased FAM19A5-A488 binding to HEK293 cells, indicating that FN can compete with FAM19A5 ( Figure 5D ). 
Discussion
Quantitative levels of FAM19A5 total transcripts, isoform 1, and isoform 2 were investigated in a wide variety of peripheral tissues and compared to levels of specific brain regions. In general, FAM19A5 transcript levels in the peripheral tissues were very low when compared with brain tissue levels. We hypothesize that isoform 2 is the major form of FAM19A5 in peripheral tissues and that isoform 1 is minimally expressed in these tissues. In contrast, the brain tissues expressed isoforms 1 and 2 equally. Isoform 1 produces a mature secretory protein 3 and isoform 2 primarily produces a plasma membrane-bound protein 4 . Isoform 2 also produces small quantities of the secretory protein 3 . Thus, the soluble secretory form of FAM19A5 is produced at lower quantities in the peripheral tissues than in the brain. Similar to the low levels of FAM19A5 transcripts that were measured in the peripheral tissues, FAM19A5 promoter-driven X-gal signals were also very faint or negligible for peripheral tissues when compared to the signal in the brain. Only a few samples exhibited faint to moderate X-gal signals. These cells included cardiac muscle cells, gastrointestinal cells (likely smooth muscle cells or mesenteric plexuses) in the muscularis externa, and germ cells in the testis and ovary. We did not detect X-gal signals in any other tissues including white adipose tissue and the thyroid and adrenal glands. Because both the X-gal intensity and the total transcript levels were very low in the peripheral tissues when compared to the brain, we conclude that the levels of FAM19A5 protein produced in these cells/tissues are likely very low. The functional relevance of these low-level proteins in the peripheral tissues needs to be investigated further.
It is intriguing that no FAM19A5 promoter-driven X-gal signals were observed in adipose tissue cells, even though these tissues cells are reported to produce significantly high levels of both FAM19A5 transcripts and protein 3 . Furthermore, our qRT-PCR results demonstrated that the transcript levels measured in white and brown adipose tissues were significantly lower than brain tissue levels. Our data is in agreement with The Human Protein Atlas Database (https://www.proteinatlas.org) which includes three independent datasets (HPA, https://www.proteinatlas.org/;
GTEx, https://gtexportal.org/; and FANTOM5, http://fantom.gsc.riken.jp/5/) that show FAM19A5 transcript levels in human adipose tissue is approximately 1/100 to 1/50 the amount found in human brain tissue [33] [34] [35] . These datasets also show extremely low levels of FAM19A5 transcripts in peripheral tissues and low-to-moderate expression levels in female and male reproductive tissues. Western blotting analysis for FAM19A5 expression in WT and FAM19A5 KO mice is also in agreement with the available data. FAM19A5 protein in adipose and reproductive tissues was below detectable levels, but brain tissue expression was high.
We were unable to observe X-gal signals in the bone marrow, thymus, and spleen, which are blood cell-producing organs 36 . Thus, the low levels of FAM19A5 transcripts in peripheral tissues raise questions about the origin of FAM19A5 in the blood. Recently, blood FAM19A5 levels were measured in human 9 and mouse samples 3 . The blood levels of FAM19A5 that were measured by ELISA ranged from 100 pg/ml for human samples 9 to 400 ng/ml for mouse samples 3 . In addition, a proteomic approach revealed that FAM19A5 was a novel serum biomarker that could be used to differentiate cholangiocarcinoma from benign biliary tract diseases 37 . There are many possible sources of FAM19A5 in the blood. FAM19A5 transcript levels are up-regulated under certain pathological conditions. For example, traumatic brain injury increased FAM19A5 transcription in a subset of neurons found in the injury penumbra and a subset of OPCs found in the corpus callosum 5 . In this case, FAM19A5 produced in the brain crossed over the blood-brain barrier to increase blood levels of FAM19A5. FAM19A5 was also expressed in a subpopulation of blood vessel endothelial cells and pericytes 5 ; therefore, these cells could be another possible source of blood FAM19A5 during disease. In the context of tumor cells, The Human Protein Atlas Database (https://www.proteinatlas.org) reports high FAM19A5 transcript levels in glioma, pancreatic cancer, and melanoma 22 . These data suggest that tumor cells themselves can be a source of blood FAM19A5.
In contrast to the previously published study, our data showed that FAM19A5 does not interact with S1PR2 to induce receptor-mediated G-protein activation and β-arrestin recruitment that leads to receptor internalization. We showed that FAM19A5 can bind to and be internalized by HEK293 cells independent of S1PR2. Furthermore, the binding and internalization events were inhibited by pretreatment with ECM molecules. FAM19A5 interacts with ECM molecules in either a competitive or antagonistic manner, which can contribute to functional modulation of the ECM under pathological conditions. In summary, FAM19A5 transcription and protein levels in peripheral tissues were significantly lower than brain tissue levels. A subset of muscle cells in the heart, GI tract, and testis was FAM19A5 promoter-driven X-gal positive. However, the cells in most peripheral tissues including adipose tissues, bone marrow, the thymus, and the spleen were X-gal negative. This study does not exclude the possibility that FAM19A5 transcript/protein levels in the periphery tissues can increase under pathological conditions, which are already suggested by GWAS and RNA-seq analyses that revealed associations between the FAM19A5 gene and peripheral disease and tumorigenesis. Therefore, this study determined basal levels of FAM19A5 transcripts and protein in peripheral tissues, providing the foundational basis to investigate peripheral FAM19A5 function under pathophysiological conditions.
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